Nepomuceno de Andrade Gisele, Bosch-Nicolau Pau, Nascimento Bruno R, Martins-Melo Francisco Rogerlândio, Perel Pablo, Geissbühler Yvonne, Demacq Caroline, Quijano Monica, Mosser Jonathan F, Cousin Ewerton, Machado Ísis Eloah, Rodrigues Matheus Lucca A C, Ribeiro Antonio Luiz P, Molina Israel
Department of Maternal and Child Nursing and Public Health, Nursing School, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
International Health Unit Vall d'Hebron-Drassanes, Infectious Diseases Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Spain.
Lancet Reg Health Eur. 2024 Sep 6;46:101040. doi: 10.1016/j.lanepe.2024.101040. eCollection 2024 Nov.
Chagas disease (CD), endemic in 21 Latin American countries, has gradually spread beyond its traditional borders due to migratory movements and emerging as a global health concern. We conducted a systematic review and meta-analysis of available data to establish updated prevalence estimates of CD in Latin American migrants residing in non-endemic countries.
A systematic search was conducted in MEDLINE/PubMed, Embase, Cochrane Library, Scopus, Web of Science, and LILACS via Virtual Health Library (), including references published until November 1st, 2023. Pooled prevalence estimates and 95% confidence intervals (CI) were calculated using random effect models. Heterogeneity was assessed by the chi-square test and the I statistic. Subgroup analyses were performed to explore potential sources of heterogeneity among studies. The study was registered in the PROSPERO database (CRD42022354237).
From a total of 1474 articles screened, 51 studies were included. Studies were conducted in eight non-endemic countries (most in Spain), between 2006 and 2023, and involving 82,369 screened individuals. The estimated pooled prevalence of CD in Latin American migrants living in non-endemic countries was 3.5% (95% CI: 2.5-4.7; I: 97.7%), considering studies in which screening was indicated simply because the person was Latin American. Per subgroups, the pooled CD prevalence was 11.0% (95% CI: 7.7-15.5) in non-targeted screening (unselected population in reference centers) (27 studies); in blood donors (4 studies), the pooled prevalence was 0.8% (95% CI: 0.2-3.4); among people living with HIV Latin American immigrants (4 studies) 2.4% (95% CI: 1.4-4.3) and for Latin American pregnant and postpartum women (14 studies) 3.7% (95 CI: 2.4-5.6). The pooled proportion of congenital transmission was 4.4% (95% CI: 3.3-5.8). Regarding the participants' country of origin, 7964 were from Bolivia, of which 1715 (21,5%) were diagnosed with CD, and 21,304 were from other Latin American countries of which 154 (0,72%) were affected.
CD poses a significant burden of disease in Latin American immigrants in non-endemic countries, suggesting that CD is no longer a problem limited to the American continent and must be considered as a global health challenge.
This study was funded by the World Heart Federation, through a research collaboration with Novartis Pharma AG.
恰加斯病(CD)在21个拉丁美洲国家流行,由于人口迁移,该病已逐渐蔓延至传统边界之外,成为全球卫生问题。我们对现有数据进行了系统评价和荟萃分析,以更新居住在非流行国家的拉丁美洲移民中恰加斯病的患病率估计。
通过虚拟健康图书馆对MEDLINE/PubMed、Embase、Cochrane图书馆、Scopus、科学网和LILACS进行系统检索,纳入截至2023年11月1日发表的参考文献。使用随机效应模型计算合并患病率估计值和95%置信区间(CI)。通过卡方检验和I统计量评估异质性。进行亚组分析以探索研究间异质性的潜在来源。该研究已在PROSPERO数据库(CRD42022354237)中注册。
在总共筛选的1474篇文章中,纳入了51项研究。研究于2006年至2023年期间在8个非流行国家(大多数在西班牙)进行,涉及82369名接受筛查的个体。考虑到仅因个体为拉丁美洲人而进行筛查的研究,居住在非流行国家的拉丁美洲移民中恰加斯病的合并患病率估计为3.5%(95%CI:2.5-4.7;I:97.7%)。按亚组划分,在非针对性筛查(参考中心的未选人群)中(27项研究),恰加斯病合并患病率为11.0%(95%CI:7.7-15.5);在献血者中(4项研究),合并患病率为0.8%(95%CI:0.2-3.4);在感染艾滋病毒的拉丁美洲移民中(4项研究)为2.4%(95%CI:1.4-4.3),在拉丁美洲孕妇和产后妇女中(14项研究)为3.7%(95%CI:2.4-5.6)。先天性传播的合并比例为4.4%(95%CI:3.3-5.8)。关于参与者的原籍国,7964人来自玻利维亚,其中1715人(21.5%)被诊断患有恰加斯病,21304人来自其他拉丁美洲国家,其中154人(0.72%)患病。
恰加斯病给非流行国家的拉丁美洲移民带来了重大疾病负担,这表明恰加斯病不再是仅限于美洲大陆的问题,必须被视为一项全球卫生挑战。
本研究由世界心脏联合会资助,通过与诺华制药公司的研究合作进行。